PCPC3 advocates for long-term funding increase for DoD PCRP

PCPC3 — the the patient-centered prostate cancer collaborative coalition — has just issued a detailed statement in strong support of an increase in the funding for the Prostate Cancer Research Program (PCRP) within the US Department of Defense. … READ MORE …

PCPC3 comments on recent data on active surveillance from Johns Hopkins

According to a message sent out earlier today by PCPC3 — the patient-centered prostate cancer collaborative coalition — the members of the coalition are “pleased to see the recently published report by Tosoian et al. indicating a 99.9% prostate cancer-specific survival rate at 10 and 15 years post-diagnosis”. … READ MORE …